Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2006

View Archived Issues

EAGLE study of Axxion stent meets primary endpoint

NicOx signs new ophthalmology agreement with Pfizer

Takeda selects cardiovascular target from Lexicon alliance

Nonapprovable letter for Emezine

Nastech reacquires rights to PYY3-36 nasal spray from Merck

Applied Biosystems completes acquisition of Ambion's Research Products Division

Keryx studies KRX-0401 for refractory leukemias

Sangamo licenses use of MaxCyte's cell loading system

Evizon 40 mg safe and active in stabilizing vision in wet AMD

Ganite effective compared with Aredia in cancer-related hypercalcemia

Oral NV-52 demonstrates rapid absorption and appreciable plasma levels

Endocannabinoid-derived topical treatment for atopic dermatitis

New inhibitor of PDGFR autophosphorylation for cell-proliferative disorders

Lucentis submitted for European approval for wet AMD

Novartis seeks European approval for Exforge

Priority review for Revlimid sNDA

Novel antiinfective agents covered in recent patents

Neupro receives approvable letter for early Parkinson's disease

Monoclonal antibody induces regression of HGF-dependent tumors in mice

Recent Pfizer, Gruenenthal and AstraZeneca patents report novel analgesic agents

Recent patents report novel agents for metabolic disorders

Clinical study of pollen extract preparation in CNBP/CPPS

R-850 shows good safety and efficacy profile in actinic keratosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...